Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD

Fox Run Management L.L.C. acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 70,115 shares of the biopharmaceutical company’s stock, valued at approximately $553,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Amicus Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 29,534,029 shares of the biopharmaceutical company’s stock valued at $232,728,000 after purchasing an additional 126,441 shares during the period. Vestal Point Capital LP grew its stake in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after buying an additional 7,625,000 shares in the last quarter. State Street Corp raised its holdings in Amicus Therapeutics by 21.5% during the 2nd quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after acquiring an additional 2,049,078 shares during the period. Bank of America Corp DE lifted its position in shares of Amicus Therapeutics by 20.7% during the second quarter. Bank of America Corp DE now owns 6,847,275 shares of the biopharmaceutical company’s stock worth $39,235,000 after acquiring an additional 1,172,596 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in shares of Amicus Therapeutics by 223.9% in the second quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock worth $19,865,000 after acquiring an additional 2,396,410 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on FOLD shares. Guggenheim lowered Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Leerink Partners cut Amicus Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $17.00 to $14.50 in a research report on Monday, December 29th. Citigroup reissued a “neutral” rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price on the stock. in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Hold” and an average price target of $15.39.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.37 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $14.38. The company has a current ratio of 2.84, a quick ratio of 2.09 and a debt-to-equity ratio of 1.43. The company has a market cap of $4.51 billion, a PE ratio of -179.63 and a beta of 0.38. The stock has a 50-day moving average price of $14.29 and a 200-day moving average price of $10.68.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The company had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. During the same period in the prior year, the business earned $0.09 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the sale, the chief executive officer owned 1,021,180 shares of the company’s stock, valued at $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Michael Clark sold 25,642 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $14.17, for a total value of $363,347.14. Following the completion of the transaction, the insider owned 245,690 shares of the company’s stock, valued at $3,481,427.30. The trade was a 9.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 218,798 shares of company stock worth $2,710,962. Corporate insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.